Literature DB >> 21641195

Modulation of leukotriene D4 attenuates the development of seizures in mice.

Ashish K Rehni1, Thakur Gurjeet Singh.   

Abstract

The present study has been designed to pharmacologically investigate the effect of Montelukast sodium, a leukotriene D(4) receptor antagonist, and 1,2,3,4, tetrahydroisoquinoline, a leukotriene D(4) synthetic pathway inhibitor, on the pathophysiological progression of seizures using mouse models of kindled epilepsy and status epilepticus induced spontaneous recurrent seizures. Pentylenetetrazole (40 mg kg(-1)) (PTZ) administration every second day for a period of 15 d was used to elicit chemically induced kindled seizure activity in mice. In a separate set of groups, fifty consecutive electroshocks were delivered to mice using corneal electrodes with continuously increasing intensity with an inter-shock interval of 40s. Severity of kindled seizures was assessed in terms of a composite kindled seizure severity score (KSSS). Pilocarpine (100 mg kg(-1)) was injected every twenty minutes until the onset of status epilepticus. A spontaneous recurrent seizure severity score (SRSSS) was recorded as a measure of quantitative assessment of the progressive development of spontaneous recurrent seizures induced after pilocarpine status epilepticus. Sub-acute PTZ administration and electroshock induced the development of severe form of kindled seizures in mice. Severity of kindled seizures was assessed in terms of a composite kindled seizure severity score. Further, pharmacological status epilepticus elicited a progressive evolution of spontaneous recurrent seizures in the animals. However, Montelukast sodium, a leukotriene D(4) receptor antagonist, as well as 1,2,3,4, tetrahydroisoquinoline, a leukotriene D(4) synthetic pathway inhibitor, markedly and dose dependently suppressed the development of kindled seizures as well as pilocarpine induced spontaneous recurrent seizures. Therefore, leukotriene D(4) may be implicated in the pathogenesis of seizures.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21641195     DOI: 10.1016/j.plefa.2011.04.003

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  10 in total

Review 1.  Pharmacological modulation of cytokines correlating neuroinflammatory cascades in epileptogenesis.

Authors:  Shubham Vishwakarma; Shareen Singh; Thakur Gurjeet Singh
Journal:  Mol Biol Rep       Date:  2021-11-09       Impact factor: 2.316

2.  Emerging perspectives on mitochondrial dysfunctioning and inflammation in epileptogenesis.

Authors:  Shareen Singh; Thakur Gurjeet Singh
Journal:  Inflamm Res       Date:  2021-10-15       Impact factor: 4.575

3.  Imatinib Attenuates Pentylenetetrazole Kindled and Pilocarpine Induced Recurrent Spontaneous Seizures in Mice.

Authors:  Shareen Singh; Thakur Gurjeet Singh
Journal:  Neurochem Res       Date:  2022-10-14       Impact factor: 4.414

4.  Montelukast inhibits pentylenetetrazol-induced seizures in rats.

Authors:  Betul Cevik; Volkan Solmaz; Durdane Aksoy; Oytun Erbas
Journal:  Med Sci Monit       Date:  2015-03-24

5.  Montelukast reduces seizures in pentylenetetrazol-kindled mice.

Authors:  J Fleck; F R Temp; J R Marafiga; A C Jesse; L H Milanesi; L M Rambo; C F Mello
Journal:  Braz J Med Biol Res       Date:  2016-02-23       Impact factor: 2.590

Review 6.  Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases.

Authors:  Paolo Gelosa; Francesca Colazzo; Elena Tremoli; Luigi Sironi; Laura Castiglioni
Journal:  Mediators Inflamm       Date:  2017-05-10       Impact factor: 4.711

Review 7.  The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids.

Authors:  Keith A Kwan Cheung; Hassendrini Peiris; Geoffrey Wallace; Olivia J Holland; Murray D Mitchell
Journal:  Int J Mol Sci       Date:  2019-12-02       Impact factor: 5.923

Review 8.  Montelukast: The New Therapeutic Option for the Treatment of Epilepsy.

Authors:  Bekalu Amare Tesfaye; Haftom Gebregergs Hailu; Kaleab Alemayehu Zewdie; Muluken Altaye Ayza; Derbew Fikadu Berhe
Journal:  J Exp Pharmacol       Date:  2021-01-20

9.  Anticonvulsive Effects of Chondroitin Sulfate on Pilocarpine and Pentylenetetrazole Induced Epileptogenesis in Mice.

Authors:  Shareen Singh; Thakur Gurjeet Singh; Manjinder Singh; Agnieszka Najda; Renata Nurzyńska-Wierdak; Rafa Almeer; Mohamed Kamel; Mohamed M Abdel-Daim
Journal:  Molecules       Date:  2021-11-09       Impact factor: 4.411

Review 10.  Cannabidiol and Neurodevelopmental Disorders in Children.

Authors:  Keith A Kwan Cheung; Murray D Mitchell; Helen S Heussler
Journal:  Front Psychiatry       Date:  2021-05-21       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.